Comparative Efficacy and Safety of Six Non-ergot Dopamine-receptor Agonists in Early Parkinson's Disease: a Systematic Review and Network Meta-analysis

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 Jul 3

PMID 37396766

Authors

Xiang-Ting Chen

Qian Zhang

Fei-Fei Chen

Si-Yuan Wen

Chang-Qing Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Non-ergot dopamine agonists (NEDAs) have been used as monotherapy or as an adjunctive therapy to levodopa for many years. Novel long-acting formulations of NEDAs including pramipexole extended-release (ER), ropinirole prolonged-release (PR), and rotigotine transdermal patch have been developed. However, there is no strong evidence that a given NEDA is more potent than another. We performed a systematic review and network meta-analysis to evaluate the efficacy, tolerability and safety of six commonly used NEDAs in early Parkinson's disease (PD).

Methods: Six NEDAs including piribedil, rotigotine transdermal patch, pramipexole immediate-release (IR)/ER, and ropinirole IR/PR were investigated. The efficacy outcomes including Unified Parkinson's Disease Rating Scale activities in daily life (UPDRS-II), motor function (UPDRS-III), and their subtotal (UPDRS-II + III), tolerability and safety outcomes were analyzed.

Results: A total of 20 RCTs (5,355 patients) were included in the current study. The result indicated that compared with placebo, all six investigated drugs had statistically significant differences in the improvement of UPDRS-II, UPDRS-III, and UPDRS-II + III (except ropinirole PR in UPDRS-II). There were no statistically significant differences between six NEDAs for the UPDRS-II and UPDRS-III. For UPDRS-II + III, the improvement of ropinirole IR/PR and piribedil were higher than that of rotigotine transdermal patch, and piribedil was higher than that of pramipexole IR. The surface under the cumulative ranking curve (SUCRA) indicated that piribedil resulted in best improvement in UPDRS-II and UPDRS-III (0.717 and 0.861, respectively). For UPDRS-II + III, piribedil and ropinirole PR exhibited similar improvement and both had high rates (0.858 and 0.878, respectively). Furthermore, piribedil performed better as monotherapy, ranking first in the improvement of UPDRS-II, III, and II + III (0.922, 0.960, and 0.941, separately). With regard to tolerability, there was a significant increase in overall withdrawals with pramipexole ER (0.937). In addition, the incidence of adverse reaction of ropinirole IR was relatively high (nausea: 0.678; somnolence: 0.752; dizziness: 0.758; fatigue: 0.890).

Conclusions: In this systematic review and network meta-analysis of six NEDAs, piribedil exhibited better efficacy, especially as monotherapy, and ropinirole IR was associated with a higher incidence of adverse events in patients with early PD.

Citing Articles

Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data.

Mu L, Xu J, Ye X, Jiang Y, Yi Z BMC Pharmacol Toxicol. 2025; 26(1):54.

PMID: 40065414 PMC: 11892196. DOI: 10.1186/s40360-025-00886-3.

Dopamine agonists in the treatment of Parkinson's disease: the show must go on.

Jost W J Neural Transm (Vienna). 2024; 131(12):1471-1480.

PMID: 39261330 DOI: 10.1007/s00702-024-02825-8.

References

Li B, Cui J, Song J, Qi C, Ma P, Wang Y . Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson's Disease: a Network Meta-Analysis. Cell Physiol Biochem. 2018; 45(1):119-130. DOI: 10.1159/000486252. View

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

Rascol O, Dubois B, Castro Caldas A, Senn S, Del Signore S, Lees A . Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. Mov Disord. 2006; 21(12):2110-5. DOI: 10.1002/mds.21122. View

Li B, Bi Z, Liu J, Si W, Shi Q, Xue L . Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison. CNS Neurosci Ther. 2017; 23(10):827-842. PMC: 6492757. DOI: 10.1111/cns.12727. View

Stocchi F, Hersh B, Scott B, Nausieda P, Giorgi L . Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008; 24(10):2883-95. DOI: 10.1185/03007990802387130. View

Chen F, Jin L, Nie Z . Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials. J Pharm Pharm Sci. 2017; 20(0):285-294. DOI: 10.18433/J3Q35D. View

Sampaio C, Bronzova J, Hauser R, Lang A, Rascol O, van de Witte S . Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord. 2011; 26(8):1464-76. DOI: 10.1002/mds.23590. View

Sethi K, OBRIEN C, Hammerstad J, Adler C, Davis T, Taylor R . Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol. 1998; 55(9):1211-6. DOI: 10.1001/archneur.55.9.1211. View

Zhou C, Lou J, Zhang Y, Zhong L, Chen Y, Lu F . Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014; 20(4):368-76. PMC: 6493117. DOI: 10.1111/cns.12239. View

10.

Tran T, Brophy J, Suissa S, Renoux C . Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson's Disease: A Systematic Review of Observational Studies. CNS Drugs. 2015; 29(12):985-98. DOI: 10.1007/s40263-015-0293-4. View

11.

Jankovic J, Watts R, Martin W, Boroojerdi B . Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007; 64(5):676-82. DOI: 10.1001/archneur.64.5.676. View

12.

Singer C, Lamb J, Ellis A, Layton G . A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Mov Disord. 2007; 22(4):476-82. DOI: 10.1002/mds.21361. View

13.

Ziegler M, Castro-Caldas A, Del Signore S, Rascol O . Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord. 2003; 18(4):418-25. DOI: 10.1002/mds.10359. View

14.

Abrams K, Gillies C, Lambert P . Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat Med. 2005; 24(24):3823-44. DOI: 10.1002/sim.2423. View

15.

Adler C, Sethi K, Hauser R, Davis T, Hammerstad J, Bertoni J . Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997; 49(2):393-9. DOI: 10.1212/wnl.49.2.393. View

16.

Dias S, Sutton A, Welton N, Ades A . Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 2013; 33(5):618-40. PMC: 3704206. DOI: 10.1177/0272989X13485157. View

17.

Mizuno Y, Nomoto M, Kondo T, Hasegawa K, Murata M, Takeuchi M . Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2013; 28(10):1447-50. DOI: 10.1002/mds.25537. View

18.

Millan M . From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Ther. 2010; 128(2):229-73. DOI: 10.1016/j.pharmthera.2010.06.002. View

19.

Delenclos M, Jones D, McLean P, Uitti R . Biomarkers in Parkinson's disease: Advances and strategies. Parkinsonism Relat Disord. 2015; 22 Suppl 1:S106-10. PMC: 5120398. DOI: 10.1016/j.parkreldis.2015.09.048. View

20.

. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003; 60(12):1721-8. DOI: 10.1001/archneur.60.12.1721. View